Literature DB >> 25787136

Identification of pertussis-specific effector memory T cells in preschool children.

Lia de Rond1, Rose-Minke Schure2, Kemal Öztürk2, Guy Berbers2, Elisabeth Sanders3, Inonge van Twillert2, Maria Carollo4, Françoise Mascart5, Clara M Ausiello4, Cecile A C M van Els2, Kaat Smits5, Anne-Marie Buisman2.   

Abstract

Whooping cough remains a problem despite vaccination, and worldwide resurgence of pertussis is evident. Since cellular immunity plays a role in long-term protection against pertussis, we studied pertussis-specific T-cell responses. Around the time of the preschool acellular pertussis (aP) booster dose at 4 years of age, T-cell memory responses were compared in children who were primed during infancy with either a whole-cell pertussis (wP) or an aP vaccine. Peripheral blood mononuclear cells (PBMCs) were isolated and stimulated with pertussis vaccine antigens for 5 days. T cells were characterized by flow-based analysis of carboxyfluorescein succinimidyl ester (CFSE) dilution and CD4, CD3, CD45RA, CCR7, gamma interferon (IFN-γ), and tumor necrosis factor alpha (TNF-α) expression. Before the aP preschool booster vaccination, both the proliferated pertussis toxin (PT)-specific CD4(+) and CD8(+) T-cell fractions (CFSE(dim)) were higher in aP- than in wP-primed children. Post-booster vaccination, more pertussis-specific CD4(+) effector memory cells (CD45RA(-) CCR7(-)) were induced in aP-primed children than in those primed with wP. The booster vaccination did not appear to significantly affect the T-cell memory subsets and functionality in aP-primed or wP-primed children. Although the percentages of Th1 cytokine-producing cells were alike in aP- and wP-primed children pre-booster vaccination, aP-primed children produced more Th1 cytokines due to higher numbers of proliferated pertussis-specific effector memory cells. At present, infant vaccinations with four aP vaccines in the first year of life result in pertussis-specific CD4(+) and CD8(+) effector memory T-cell responses that persist in children until 4 years of age and are higher than those in wP-primed children. The booster at 4 years of age is therefore questionable; this may be postponed to 6 years of age.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25787136      PMCID: PMC4412945          DOI: 10.1128/CVI.00695-14

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  37 in total

1.  Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose.

Authors:  Hans O Hallander; Lennart Gustafsson; Margaretha Ljungman; Jann Storsaeter
Journal:  Vaccine       Date:  2005-07-01       Impact factor: 3.641

2.  Long-term humoral and cell-mediated immunity after acellular pertussis vaccination compares favourably with whole-cell vaccines 6 years after booster vaccination in the second year of life.

Authors:  N Guiso; E Njamkepo; F Vié le Sage; F Zepp; C U Meyer; V Abitbol; N Clyti; S Chevallier
Journal:  Vaccine       Date:  2006-11-07       Impact factor: 3.641

3.  Immunity to pertussis 5 years after booster immunization during adolescence.

Authors:  Kati Edelman; Qiushui He; Johanna Mäkinen; Anna Sahlberg; Marjo Haanperä; Lode Schuerman; Joanne Wolter; Jussi Mertsola
Journal:  Clin Infect Dis       Date:  2007-04-02       Impact factor: 9.079

4.  Improving the cellular pertussis vaccine: increased potency and consistency.

Authors:  Marcel Thalen; Arno van der Ark; Jan van den Ijssel; Ineke van Straaten; Dennis Jansen; Coen Beuvery; Dirk Martens; Johannes Tramper
Journal:  Vaccine       Date:  2007-12-05       Impact factor: 3.641

5.  IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content.

Authors:  Lotte H Hendrikx; Guy A M Berbers; Reinier H Veenhoven; Elisabeth A M Sanders; Anne-Marie Buisman
Journal:  Vaccine       Date:  2009-09-01       Impact factor: 3.641

6.  Functional and phenotypic characterization of tetanus toxoid-specific human CD4+ T cells following re-immunization.

Authors:  Cristina Cellerai; Alexandre Harari; Florence Vallelian; Onur Boyman; Giuseppe Pantaleo
Journal:  Eur J Immunol       Date:  2007-04       Impact factor: 5.532

7.  Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines.

Authors:  C M Ausiello; F Urbani; A la Sala; R Lande; A Cassone
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

Review 8.  Phenotype and function of human T lymphocyte subsets: consensus and issues.

Authors:  Victor Appay; Rene A W van Lier; Federica Sallusto; Mario Roederer
Journal:  Cytometry A       Date:  2008-11       Impact factor: 4.355

9.  Long-term presence of memory B-cells specific for different vaccine components.

Authors:  A M Buisman; C G H de Rond; K Oztürk; H I Ten Hulscher; R S van Binnendijk
Journal:  Vaccine       Date:  2009-09-30       Impact factor: 3.641

Review 10.  B-cell responses to vaccination at the extremes of age.

Authors:  Claire-Anne Siegrist; Richard Aspinall
Journal:  Nat Rev Immunol       Date:  2009-03       Impact factor: 53.106

View more
  11 in total

Review 1.  Waning and aging of cellular immunity to Bordetella pertussis.

Authors:  Inonge van Twillert; Wanda G H Han; Cécile A C M van Els
Journal:  Pathog Dis       Date:  2015-09-13       Impact factor: 3.166

Review 2.  What Is Wrong with Pertussis Vaccine Immunity? Why Immunological Memory to Pertussis Is Failing.

Authors:  Dimitri A Diavatopoulos; Kathryn Margaret Edwards
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-12-01       Impact factor: 10.005

Review 3.  Immune persistence after pertussis vaccination.

Authors:  Zhiyun Chen; Qiushui He
Journal:  Hum Vaccin Immunother       Date:  2017-01-03       Impact factor: 3.452

4.  Th1/Th17 polarization persists following whole-cell pertussis vaccination despite repeated acellular boosters.

Authors:  Ricardo da Silva Antunes; Mariana Babor; Chelsea Carpenter; Natalie Khalil; Mario Cortese; Alexander J Mentzer; Grégory Seumois; Christopher D Petro; Lisa A Purcell; Pandurangan Vijayanand; Shane Crotty; Bali Pulendran; Bjoern Peters; Alessandro Sette
Journal:  J Clin Invest       Date:  2018-08-06       Impact factor: 14.808

Review 5.  What Is Wrong with Pertussis Vaccine Immunity? The Problem of Waning Effectiveness of Pertussis Vaccines.

Authors:  Nicolas Burdin; Lori Kestenbaum Handy; Stanley A Plotkin
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-12-01       Impact factor: 10.005

Review 6.  Association of Pertussis Toxin with Severe Pertussis Disease.

Authors:  Karen Scanlon; Ciaran Skerry; Nicholas Carbonetti
Journal:  Toxins (Basel)       Date:  2019-06-27       Impact factor: 4.546

Review 7.  Vaccine-Induced Cellular Immunity against Bordetella pertussis: Harnessing Lessons from Animal and Human Studies to Improve Design and Testing of Novel Pertussis Vaccines.

Authors:  Anja Saso; Beate Kampmann; Sophie Roetynck
Journal:  Vaccines (Basel)       Date:  2021-08-07

8.  A system-view of Bordetella pertussis booster vaccine responses in adults primed with whole-cell versus acellular vaccine in infancy.

Authors:  Ricardo da Silva Antunes; Ferran Soldevila; Mikhail Pomaznoy; Mariana Babor; Jason Bennett; Yuan Tian; Natalie Khalil; Yu Qian; Aishwarya Mandava; Richard H Scheuermann; Mario Cortese; Bali Pulendran; Christopher D Petro; Adrienne P Gilkes; Lisa A Purcell; Alessandro Sette; Bjoern Peters
Journal:  JCI Insight       Date:  2021-04-08

Review 9.  Roads to the development of improved pertussis vaccines paved by immunology.

Authors:  Jolanda Brummelman; Mieszko M Wilk; Wanda G H Han; Cécile A C M van Els; Kingston H G Mills
Journal:  Pathog Dis       Date:  2015-09-06       Impact factor: 3.166

10.  Whole-Cell or Acellular Pertussis Primary Immunizations in Infancy Determines Adolescent Cellular Immune Profiles.

Authors:  Saskia van der Lee; Lotte H Hendrikx; Elisabeth A M Sanders; Guy A M Berbers; Anne-Marie Buisman
Journal:  Front Immunol       Date:  2018-01-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.